Clinical trials: Depressive State
Major Depressive Disorder
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
- Trial name
- NCT05655507
- Testing
- Zuranolone
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biogen
Depressive Disorder, Major
Alpha-Stim AID and Major Depressive Disorder
The study will be a multi-centre parallel group, double blind, non-commercial, randomised controlled superiority trial. Study participants will be referred from Primary Care GP practices via their GP and randomised into active…
- Trial name
- NCT04963907
- Testing
- Active Alpha-Stim CES
- Where
- United Kingdom
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Electromedical Products International, Inc.
Depressive Symptoms, Urinary Incontinence
BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and Early Post-Childbirth Women
The goal of this clinical trial is to evaluate if the combined treatment with EXOMIND (BTL-699-2) and EMSELLA (HPM-6000UF) devices is able to improve depressive symptoms and urinary incontinence in women who delivered a healthy…
- Trial name
- NCT07413692
- Testing
- EXOMIND (BTL-699-2) ActiveTreatment, EMSELLA (HPM-6000UF) ActiveTreatment
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- BTL Industries Ltd.
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Depression, Anxiety
Meru Health Program for Cancer Patients With Depression and Anxiety
The primary objective of this study is to evaluate clinical outcomes among people with cancer who participate in a 12-week therapist-supported digital mental health intervention (DMHI) called the Meru Health Program (MHP).
- Trial name
- NCT05588622
- Testing
- Meru Health Program
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Meru Health, Inc.
Depression, Postpartum
IMI PROTECT(WP2): Antidepressants & Fractures
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 and Workgroup 1.
- Trial name
- NCT01587729
- Testing
- Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Cancer Pain
Case-control Study- Cancer Pain: Uncontrolled Pain as Depression Development Predictor in Oncologic Patients (Fentanyl)
The purpose of this study is to evaluate the relationship between cancer pain and risk of depression among cancer patients.
- Trial name
- NCT01402830
- Testing
- Visual analogue scales (EVAs)
- Volunteers
- 271 people
- Sponsor
- Janssen-Cilag, S.A.
Anxiety, Stress
Impact of a Mobile Application (Pacifica) on Stress, Anxiety, and Depression
The study is designed to examine the efficacy of a mobile application implementation of existing best practices in mental health treatment for managing stress, anxiety, and depression.
- Conditions
- Anxiety, Stress, Depression
- Trial name
- NCT03333707
- Testing
- Pacifica App
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Pacifica Labs Inc.
Depression, Depressive Disorder
Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and duloxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00366652
- Testing
- desvenlafaxine SR, desipramine, duloxetine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Opiate Induced Respiratory Depression
Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia
The study is an investigation to assess the capacity of ascending doses of CX1739 to antagonize the respiratory depressive effect of remifentanil.
- Trial name
- NCT02735629
- Testing
- CX1739 - 300 mg, CX1739 - 600 mg, CX1739 - 900 mg
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- RespireRx
Acute Cannabis-induced CNS Depression
Observational Study of THC Concentrations in Acute Cannabis-induced CNS Depression
This observational study is being conducted to determine plasma concentrations of tetrahydrocannabinol (THC) and its metabolites, 11-OH-THC and THC-COOH, in plasma of pediatric patients who visit the emergency department due to…
- Trial name
- NCT06017622
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Anebulo Pharmaceuticals
Depression
To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets
To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.
- Trial name
- NCT00913822
- Testing
- Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories), Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Major Depressive Disorder
Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder
The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.
- Trial name
- NCT00277823
- Testing
- DVS-SR 50 mg, DVS-SR 100 mg
- Where
- 25 sites in United States
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Affective Psychosis, Bipolar, Bipolar Disorder
A Study to Evaluate the Efficacy and Safety of Adjustable Doses of Extended-release (ER) Paliperidone Compared With Placebo, in Combination With Lithium or Valproate, to Treat Manic and Mixed Episodes in Patients With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety over a 6-week period of paliperidone ER compared with placebo in treating subjects with Bipolar I Disorder who are experiencing a manic or mixed episode while…
- Conditions
- Affective Psychosis, Bipolar, Bipolar Disorder, Mania
- Trial name
- NCT00309686
- Testing
- Paliperidone ER
- Volunteers
- 300 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Depression
Predicting Response to Depression Treatment (PReDicT)
Depression is a very common, serious and in some cases life-threatening condition, affecting around 350 million people globally.
- Trial name
- NCT02790970
- Testing
- PReDicT Test, Treatment as Usual
- Where
- 76 sites in France, Germany and 3 more
- Volunteers
- 913 people
- Sponsor
- P1vital Products Limited
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Depression
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
To demonstrate the relative bioavailability of fluoxetine hydrochloride capsules, 40 mg.
- Trial name
- NCT00947076
- Testing
- Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc), Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sandoz
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (UAQ, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07578142
- Testing
- Accexible
- Where
- Mexico
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Accexible
Depression
A Clinical Study of Trazodone Hydrochloride Prolonged-Release Tablets for Treatment of Depression
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of trazodone hydrochloride prolonged-release tablets for treatment of depression in Chinese population.
- Trial name
- NCT01524497
- Testing
- Trazodone
- Where
- China
- Volunteers
- 382 people
- Sponsor
- Lee's Pharmaceutical Limited
Depression, Anxiety
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy
A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy.
- Conditions
- Depression, Anxiety, Major Depressive Disorder, Generalized Anxiety Disorder
- Trial name
- NCT03591224
- Testing
- Pharmacogenomic Testing, Pharmacist Standard of Care
- Where
- 2 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- John Papastergiou Pharmacy Ltd